Sally Church on Pharma Strategy Blog continues her new products focus with a recent post on “FGFR1 mutations in squamous cell lung cancer”.
As Sally notes, squamous cell carcinomas account for 25% of new lung carcinomas and 40,000 deaths per year in the United States. There is currently no FDA approved targeted therapy for this cancer.
In her insightful blog post Sally discusses recent research on FGFR1 mutations using Pfizer’s pan-FGFR inhibitor PD173074. She concludes the research is promising, but that “preclinical research is no guarantee of success in the clinic.”
Fibroglast Growth Factor Receptors (FGFR) play a potential role in carcinogenesis and may be an important target in squamous cell lung cancer. You can read more about the new products in development that seek to target them on Pharma Strategy Blog.